New Biotech Stock Alert: Moleculin Biotech Set to Begin Public Trading

Rhea-AI Filing Summary

The Securities and Exchange Commission has declared Moleculin Biotech's Form S-1 registration statement effective as of June 20, 2025, at 9:00 A.M. The Form S-1 (File Number: 333-287727) represents a significant regulatory milestone for the company.

A Form S-1 effectiveness notice typically indicates that the company has received regulatory approval to proceed with:

• Initial public offering (IPO)
• Follow-on public offering
• Registration of securities for sale to the public

This development enables Moleculin Biotech (MBRX) to move forward with its planned securities offering, having satisfied SEC registration requirements. Investors should refer to the full S-1 filing for detailed information about the offering terms, use of proceeds, and associated risks.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date:	June 20, 2025 9:00 A.M.

Form:

S-1

CIK:	0001659617
Company Name:	Moleculin Biotech, Inc.
File Number:	333-287727

FAQ

When did MBRX's S-1 registration statement become effective?

MBRX's S-1 registration statement became effective on June 20, 2025 at 9:00 A.M., as indicated in the SEC Notice of Effectiveness.

What is MBRX's CIK number for SEC filings?

Moleculin Biotech, Inc.'s (MBRX) CIK number is 0001659617, as shown in the SEC filing.

What is the file number for MBRX's S-1 registration?

The file number for MBRX's S-1 registration statement is 333-287727.

When did MBRX file their Notice of Effectiveness with the SEC?

MBRX filed their Notice of Effectiveness with the SEC on June 28, 2025, which confirmed the effectiveness of their S-1 registration statement from June 20, 2025.